Entera Bio Ltd Announces Interim Data From Phase 2 Clinical Trial of EB613 in Osteoporosis and Second Quarter 2020 Financial Results
August 20, 2020 06:30 ET
|
Entera Bio Ltd.
‒ 6-Month Interim Data Indicate EB 613 Has Meaningful and Positive Impact on Lumbar Spine Bone Mineral Density (BMD) in a Dose Dependent Manner –‒ Company Expects to Complete Patient Enrollment in...
CHF Solutions Announces Registry for Fluid Overload Conditions in Pediatric Patients
July 16, 2020 08:00 ET
|
CHF Solutions, Inc.
EDEN PRAIRIE, Minn., July 16, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to improving the lives of patients suffering from fluid overload, today...
Summit Announces Publication of Phase 2 Clinical Analyses of Gut Microbiome Health
July 13, 2020 07:00 ET
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Announces Publication of Phase 2 Clinical Analyses of Gut Microbiome Health Oxford, UK, and Cambridge, MA, US, July 13, 2020...
Clinical Trial Shows Itolizumab Reduces Mortality in Patients Hospitalized with COVID-19
July 13, 2020 03:30 ET
|
Equillium
Equillium shares topline results of patients treated with itolizumab in clinical trial conducted in India by partner Biocon Biocon has received emergency use approval from Drugs Controller General of...
Entera Bio Ltd Announces Interim Biomarker Data From Phase 2 Clinical Trial of EB613 and First Quarter 2020 Financial Results
May 21, 2020 06:30 ET
|
Entera Bio Ltd.
‒ Statistically Significant One Month Increases in P1NP Biomarker from First 50% of Patients with Highest Dose of EB613 ‒‒ Company to Follow Patients in the Phase 2 Clinical Trial of EB613 through Six...
CHF Solutions Announces COVID-19 Patients Treated with Aquadex Therapy for Fluid Management When Access to Dialysis Machines is Limited or Not Available
April 14, 2020 08:00 ET
|
CHF Solutions, Inc.
EDEN PRAIRIE, Minn., April 14, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, announced that...
CHF Solutions Announces Presentation of Clinical Data with Aquadex FlexFlow® Highlighting Efficacy and Simplicity of Use In Treating Critical Care Patients
January 08, 2020 08:00 ET
|
CHF Solutions, Inc.
EDEN PRAIRIE, Minn., Jan. 08, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS) today announced results from an investigator-initiated retrospective analysis of utilization of the Aquadex...
ideaPoint Partners with SAS to Provide Leading Data Sharing Solution Through ClinicalStudyDataRequest.com
January 07, 2020 07:00 ET
|
Anaqua
BOSTON, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Anaqua’s ideaPoint, a leading provider of innovation management solutions, today has announced a partnership with SAS, the world leader in analytics. The...
Healthcare Predictive Analytics Market To Reach USD 22,390.3 Million By 2026 | Reports And Data
November 11, 2019 21:00 ET
|
Reports and Data
New york, Nov. 11, 2019 (GLOBE NEWSWIRE) -- Exponential increase in healthcare database volume, increasing investments on digital tech to effectively manage available information, rising adoption of...
Summit Therapeutics Reports New Data from Phase 2 Clinical Trial Connecting Ridinilazole’s Microbiome Preservation to Improved Clinical Outcomes for Patients with C. difficile Infection
October 07, 2019 07:00 ET
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics Reports New Data from Phase 2 Clinical Trial Connecting Ridinilazole’s Microbiome Preservation to Improved Clinical Outcomes...